Plus deals involving Takeda/Zedira/Dr. Falk, Lupin/Sunovion, Eucure/Syncromune, Hetero/Johnson & Johnson, Nitto Denko/Omega, Harbour BioMed/CSPC and Pregene/Bone Therapeutics.

I-Mab sets commercial plans with Sinopharm for felzartamab in multiple myeloma. Legochem and Antengene team up on antibody-drug conjugates, Luoxin licenses respiratory drug from Marinomed.

Although the U.S. market for sports medicine products is dominated by conservative care products, new surgical techniques and products, including arthroscopy products and surgical implants, are fueling growth in the market, which is projected to reach almost $15.5 billion by 2018.

Although the US sports medicine market is dominated by conservative care treatments, new surgical techniques, arthroscopy products and surgical implants are fueling growth in the market, which is projected to reach almost $15.5 billion by 2018. Industry consolidation and dealmaking among orthopedic manufacturers has yielded several partnerships and M&As that have included a sports medicine element.